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In this opinion article, we intend to elaborate on thyroid mediation of isoflavone effects mainly on
the bone of aging males, which appears to have an important role but is still insufficiently analyzed
in the existing literature. Namely, the consequences of exposure to endocrine-disrupting chemicals
strongly depend on the timing of interaction and life stages of humans and animals, so we intended
to highlight the thyroid-related mechanism underlying the beneficial effect of isoflavones on aged
male bone.
Isoflavones are plant polyphenolic compounds dominantly present in legumes. Soybean
products are the main source of isoflavones in the human diet, either consumed as food or as
isolated soy protein, extracts, supplements, or purified compounds (1). In plants, isoflavones are
mainly present as 7-O-β-D-glucosides (genistin and daidzin) and only in minor amounts in their
free form as aglycones (genistein and daidzein) (1). The aglycones are biologically a more potent
form, exerting hormone-like, antioxidant, anticarcinogenic, and osteoprotective actions (1). The
potential use of isoflavones in the prevention and treatment of osteoporosis is even more actual
considering that all current treatments manifest imperfections and bear the risks of side effects
after prolonged usage (2).
Several epidemiological studies and clinical trials have revealed that supplementation with soy
isoflavones improves bone health status in early and postmenopausal women (3). In parallel, aged
men may have more bone-related benefits from isoflavone application than women, especially in
the states of physiological or iatrogenic (prostate cancer therapy) androgen deficiency (4). Given
that the number of men above the age of 70 is continuously increasing, the problem of male
osteoporosis has been recognized as a major health-care challenge (5). Combined soy protein and
isoflavone supplementation in men with type 2 diabetes mellitus led to a significant reduction in
the bone resorption marker βCTX (6). However, epidemiological and clinical evidence regarding
the bone-protective role of isoflavones in men is still scarce. In the meantime, research data on the
mechanisms of action in well-defined models of male aging should provide useful insights into the
therapeutic possibilities of isoflavones.
Thyroid hormones are known to play an important role in the regulation of bone
metabolism, while isoflavones have been shown to interfere with thyroid homeostasis. Histological
analysis of the effects of human hypothyroidism revealed low bone turnover with decreased
osteoblast and osteoclast activities, resulting in increased mineralization without changes
in bone volume (7). Crucially, the excess of thyroid hormones in hyperthyroidism results
in stimulation of osteoclastogenesis and bone resorption (8). Gene expression of thyroid
receptor (TR) α1 and β1 is confirmed in osteoclasts, but there are still doubts whether
triiodothyronine (T3) stimulates osteoclast activity directly or whether these processes result
from T3 actions in osteoblasts, osteocytes, and/or other bone cells (9, 10). When it comes
to isoflavone effects in the context of thyroid status, in vitro and in vivo studies indicate
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different mechanisms of their action, whereas the changes of
circulating thyroid hormone levels represent the outcome of
all these effects. Namely, they inhibit thyroid peroxidase (TPO)
activity by acting as competitive substrates for iodination (11).
Genistein and daidzein inhibit binding of serum transport
protein transthyretin (TTR) to thyroid hormones (12).
However, the capacity of the thyroid system to compensate
the consequences of isoflavone actions depends on numerous
factors, such as insufficient iodine in the diet, co-exposure
with other goitrogens, and age and sex (13–15). Human
studies also indicate an association between increased risk of
developing goiter on the one hand and high intake of soy-
based foods combined with iodine deficiency on the other
(11). The TPO inhibition was confirmed by identification of
iodinated isoflavones in the urine of menopausal women upon
isoflavone supplementation (16). However, although some
clinical reports indicate the absence of the effect of isoflavones
on thyroid hormone status (17), isoflavones tripled the risk
of overt hypothyroidism development in postmenopausal
women with subclinical hypothyroidism (18). There are still
no available data regarding the potential remedial action of
isoflavones on the bones in hyperthyroid states. It might be of
importance for bone preservation, considering that both clinical
and experimental studies coherently indicate that reduced bone
density, osteoporosis, and increased fracture rate are associated
with hyperthyroidism (8).
In an orchidectomized rat model of the andropause (15–16
months old Wistar males), subcutaneous application of various
doses of genistein or daidzein (10 and 30 mg/kg b.m., daily for
3 weeks) suppressed thyroid activity, decreased thyroxin (T4)
and T3, and elevated thyroid-stimulating hormone (TSH) in
serum (19, 20). Such an effect of isoflavones was potentiated
by both androgen deprivation and age (21, 22). At the same
time, treatment of middle-aged rats with isoflavones (35 mg/kg
b.m., daily for 4 weeks) elevated expression of T3-responsive
genes, Dio1 enzyme activity, and concentration of T3 in the
liver by interfering with TTR, which resulted in a mixed
phenotype of systemic hypothyroidism and local (hepatic) tissue
hyperthyroidism (12, 14). To note, thyroxin-binding globulin
(TBG) is the major serum transport protein in humans but not
TTR, while isoflavones do not compete with thyroid hormones
for binding to TBG or albumin in vitro (12). However, TTR,
in comparison with TBG, seems to be responsible for much
of the immediate delivery of thyroid hormones to human
tissues (23). Endogenous sex steroids differently influence the
synthesis and stability of TBG in men and women (24). The
treatment of middle-aged females with isoflavones under the
same experimental setup remained without effects on thyroid
homeostasis (13), which is in coherence with the fact that
the females are less susceptible to perturbation of thyroid
homeostasis (25).
In our middle-aged orchidectomized model, genistein and
daidzein improved bone microarchitecture by increasing the
cancellous bone formation, trabecular thickness, and trabecular
number but decreasing the trabecular separation, all in the
proximal tibial metaphysis (20, 26). Marked reductions in
biochemical markers of bone formation, serum osteocalcin,
and urinary Ca2+ concentrations were observed in comparison
with those in orchidectomized controls (20, 26). In addition to
this, isoflavones beneficially affected Ca2+/PI balance through
modulation of parathyroid hormone/1.25(OH)2–vitamin
D3/calcitonin balance (27). Most experimental studies also
reported beneficial effects of soy isoflavones on the bone in
male models (28, 29). Similarly, genistein (10 mg/kg b.m.)
subcutaneously administered to ovariectomized females
exerted a beneficial, bone-sparing effect by increasing bone
mineral density and lowering serum osteocalcin concentration
(30). Moreover, daidzein may be more efficient than
genistein in the remediation of ovariectomy-induced bone
loss (31).
Although the signs of systemic hypothyroidism coincided
with higher bioavailability of thyroid hormones to bones in
our model, TSH elevation was a favorable outcome within the
frame of pituitary-thyroid mediation of bone-related isoflavone
effects. TSH plays a direct role in the regulation of bone turnover
independently of thyroid hormones (32). Heterozygous Tshr+/−
mice have normal levels of thyroid hormones and TSH but
decreased bone density. Additionally, Tshr null mice have severe
osteoporosis, and supplementation with T4 could not restore
bone mass (32). Treatment of ovariectomized rats with low
doses of TSH (insufficient to alter serum T3, T4, or TSH) also
demonstrated that TSH independently prevented bone loss and
increased bone mass (33). Human studies in postmenopausal
women confirmed that subcutaneous injection of recombinant
human TSH exerts both anti-resorptive and anabolic
actions (34).
Besides general adrenocortical and thyroid functions
interconnection in the regulation of energy balance, the interplay
between glucocorticoids and hypothalamic-pituitary-thyroid
axis may reflect adversely on morphofunctional characteristics
of bone tissue. Stress conditions and glucocorticoids per se
had been long ago established as the osteoporosis-promoting
factors (35, 36). Moreover, glucocorticoids decrease thyrotropin-
releasing hormone (TRH) gene expression in the hypothalamic
paraventricular nucleus (PVN), as well as TSH serum
concentrations in both rats and humans (37, 38). Given the
previous elaboration of beneficial effects of high TSH on the
bone (39), glucocorticoid indirect input (by lowering TSH)
may also provoke the adverse effect on the bone homeostasis.
Figure 1 provides a summary of data regarding thyroid
mediation and other relevant endocrine aspects of isoflavone
effects on osteoporotic bone in aged males. Genistein and
daidzein were reported to be the strong inhibitors of 3β-HSD
and cytochrome P450 21-hydroxylase enzymes, involved in
the process of corticosteroid oogenesis (40). In our rat model,
genistein and daidzein reduced both circulating levels of
ACTH and corticosterone, thus reducing the risk of circulating
glucocorticoid “pressure” on the osteoporotic bone (20, 26, 41).
Thus, the isoflavone-glucocorticoid-TSH triad provides an
additional favorable outcome in the context of pituitary-thyroid
mediation of bone-sparing effects.
Aside from the systemic effects of isoflavones, it is noteworthy
to observe the possibility of their interference with bioavailability
and signaling of thyroid hormones within the bone tissue.
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FIGURE 1 | Thyroid mediation and other relevant endocrine aspects of isoflavone effects on osteoporotic bone in aged males. TPO, thyroid peroxidase; TH, thyroid
hormone; TSH, thyroid-stimulating hormone; TTR, transthyretin; TR, thyroid receptor; MCT8, monocarboxylate transporter-8; PTH, parathormone; CT, calcitonin; vit.
D, vitamin D. Arrows with “+” mean bone-protective effect; arrows with “–” mean bone-deteriorating effect; arrows with “#” mean local tissue changes upon androgen
deprivation within the thyroid endocrine system.
Genistein and daidzein may enhance T3-liganded, TR α
and β-mediated transcription in a concentration-dependent
manner (42). Moreover, although the role of thyroid hormone
transporters in bone is still uncertain, the expression of
monocarboxylate transporter-8 (MCT8) and L-amino acid
transporter (LAT)-1 and LAT-2 was confirmed in osteoblasts
and osteoclasts at all stages of cell differentiation (43). In
parallel, it was suggested that genistein may bind to human
MCT8 protein (44). Apart from thyroid hormone (TH)
transporters, the relative activities of type 2 and 3 deiodinases
(Dio2 and Dio3) determine intracellular availability of T3
in the bone, whereas Dio1 is not expressed in the skeleton
(43). Genistein was shown to be a Dio1-specific inhibitor,
without affecting the activity of Dio2 and Dio3 in vitro (45).
The relevance of direct putative mechanisms of isoflavone
action that might influence local tissue bioavailability and
thyroid hormone signaling in bone still awaits further in
vivo analyses.
In addition to the endocrine interference, the direct effect
of isoflavones on the osteogenesis and osteoclastogenesis is
also described, whereas selective estrogen receptor binding
(46) represents one of the most suspected mechanisms. These
compounds may also affect the paracrine activity in the bone,
calcium channel signaling, and expression of osteoblastogenesis
modulator core-binding factor 1 or receptor activator of nuclear
factor-κB (RANK) expressed by osteoclasts, together with RANK
ligand (RANKL) and osteoprotegerin (OPG) produced by
osteoblasts (47).
The biopotency of aglycones is highly questioned at the
moment because of their rapid metabolism, low serum
concentration, and bioavailability upon supplementation
(48). However, phase II of polyphenols conjugation does
not always decrease their biological activity for a number of
physiological endpoints (48). Certain isoflavone conjugates
may represent an intracellular pool for generation and
release of aglycones (49). Interestingly, the concentration
of genistein in the thyroid and mammary gland tissue was
reported to be markedly higher than in rat circulation (48).
Apart from circulation, data regarding the concentration of
isoflavones and their metabolites in bone tissue are still lacking,
as well as the information regarding their potential bone-
sparing effects, except for highly potent (S)-equol produced
from daidzein by the gut microbiota. Great variations in
response to pharmacotherapeutics, including isoflavones,
point to a personalized approach. Definition of isoflavone
metabolizing phenotypes as a strategy for identification
of individuals might benefit from osteoporosis-preventive
strategies using isoflavones.
CONCLUSION
This opinion article is founded on the fact that soy isoflavones
represent effective bioactive compounds that interfere with
thyroid cascade and signaling at various points in a sex-and-age-
dependent manner. A deeper understanding of the mechanisms
involved in thyroid-mediated isoflavone action in the bone is
even more important considering the complexity of regulation
of bone remodeling, as well as the actuality of the bone
disorders in advanced age. Potentially, therapeutic exploitation
of biomedical essence presented here may inspire further
research and development of isoflavone-based supplementation
for men suffering from endocrine disorders and secondary
osteoporosis. Basic and clinical research about isoflavone effects
in thyrotoxicosis and associated bone pathology could be of
particular interest.
Frontiers in Endocrinology | www.frontiersin.org 3 October 2019 | Volume 10 | Article 688
Šošic´-Jurjevic´ et al. Isoflavones, Pituitary-Thyroid Axis and Bone
AUTHOR CONTRIBUTIONS
All authors named have participated in the work in a
substantive way. BŠ-J the Opinion concept creator, has
written the majority of the article, analyzed the specific
topics and interpreted the results of the research group
in a broader context of literature. VA also contributed
significantly to the writing of the article and provided the
comprehensive approach to the scientific issue elaborated
in the article. BF has included his focused expertise
regarding bone microarchitecture and designed the figure.
WS has carefully read and critically revised the manuscript
for its scientific merit and intellectual content and has
supplemented the literature survey. VM has supervised
the work, carefully read the article for its scientific merit
and intellectual content as well as supplemented the
literature survey.
FUNDING
This research was supported by grants from the Ministry of
Education and Science of the Republic of Serbia (No. 173009).
REFERENCES
1. Xiao S, Zhang H, Tong S, Shi S. Comprehensive evaluation of the role of soy
and isoflavone supplementation in humans and animals over the past two
decades. Phytother Res. (2018) 32:384–94. doi: 10.1002/ptr.5966
2. Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H, et al.
Molecular-based treatment strategies for osteoporosis: a literature review. Int
J Mol Sci. (2019) 20:E2557. doi: 10.3390/ijms20102557
3. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Thatcher NJ, Kilpatrick
ES, et al. Soy reduces bone turnover markers in women during early
menopause: a randomized controlled trial. J Bone Miner Res. (2017) 32:157–
64. doi: 10.1002/jbmr.2927
4. Ajdžanovic´ V, Filipovic´ B, Miljic´ D, Mijatovic´ S, Maksimovic´-Ivanic´ D, Miler
M, et al. Prostate cancer metastasis and soy isoflavones: a dogfight over a bone.
EXCLI J. (2019) 18:106–26. doi: 10.17179/excli2018-1836
5. Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J. The clinical
epidemiology of male osteoporosis: a review of the recent literature. Clin
Epidemiol. (2015) 7:65–76. doi: 10.2147/CLEP.S40966
6. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Kilpatrick ES, Atkin
SL. Effect of soy on bone turn-over markers in men with type 2
diabetes and hypogonadism—a randomised controlled study. Sci Rep. (2017)
7:15366. doi: 10.1038/s41598-017-15402-9
7. Eriksen EF,Mosekilde L,Melsen, F. Kinetics of trabecular bone resorption and
formation in hypothyroidism: evidence for a positive balance per remodeling
cycle. Bone. (1986) 7:101–8. doi: 10.1016/8756-3282(86)90681-2
8. Bassett JH, Williams G. R. Analysis of physiological responses to thyroid
hormones and their receptors in bone. In: Plateroti M, Samarut J, editors.
Thyroid Hormone Nuclear Receptor. Methods in Molecular Biology, Vol. 1801.
New York, NY: Humana Press (2018). p. 123–54.
9. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara,
K. Thyroid hormone stimulates osteoclast differentiation by a mechanism
independent of RANKL-RANK interaction. J Cell Physiol. (2004) 201:17–
25. doi: 10.1002/jcp.20041
10. Bassett JH, Williams GR. Role of thyroid hormones in skeletal
development and bone maintenance. Endocr Rev. (2016) 37:135–
87. doi: 10.1210/er.2015-1106
11. Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity
of soy isoflavones. Environ Health Perspect. (2002) 110(Suppl.
3):349–53. doi: 10.1289/ehp.02110s3349
12. Radovic´ B, Mentrup B, Köhrle, J. Genistein and other soya isoflavones are
potent ligands for transthyretin in serum and cerebrospinal fluid. Br J Nutr.
(2006) 95:1171–6. doi: 10.1079/BJN20061779
13. Šošic´-Jurjevic´ B, Lütjohann D, Jaric´ I, Miler M, Vojnovic´ Milutinovic´ D,
Filipovic´ B, et al. Effects of age and soybean isoflavones on hepatic cholesterol
metabolism and thyroid hormone availability in acyclic female rats. Exp
Gerontol. (2017) 92:74–81. doi: 10.1016/j.exger.2017.03.016
14. Šošic´-Jurjevic´ B, Lütjohann D, Renko K, Filipovic´ B, Radulovic´ N,
AjdŽanovic´ V, et al. The isoflavones genistein and daidzein increase
hepatic concentration of thyroid hormones and affect cholesterol metabolism
in middle-aged male rats. J Steroid Biochem Mol Biol. (2019) 190:1–
10. doi: 10.1016/j.jsbmb.2019.03.009
15. Sosvorova L, Miksatkova P, Bicikova M, Kanova N, Lapcik O. The presence
of monoiodinated derivates of daidzein and genistein in human urine and
its effect on thyroid gland function. Food Chem Toxicol. (2012) 50:2774–
9. doi: 10.1016/j.fct.2012.05.037
16. Bruce B, Messina M, Spiller GA. Isoflavone supplements do not affect thyroid
function in iodine-replete postmenopausal women. J Med Food. (2003) 6:309–
16. doi: 10.1089/109662003772519859
17. Alekel DL, Genschel U, Koehler KJ, Hofmann H, Van Loan MD, Beer BS,
et al. Soy isoflavones for reducing bone loss study: effects of a 3-year trial
on hormones, adverse events, and endometrial thickness in postmenopausal
women.Menopause. (2015) 22:185–97. doi: 10.1097/GME.0000000000000280
18. Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T,
Kilpatrick ES, et al. The effect of soy phytoestrogen supplementation on
thyroid status and cardiovascular risk markers in patients with subclinical
hypothyroidism: a randomized, double-blind, crossover study. J Clin
Endocrinol Metabol. (2011) 96:1442–9. doi: 10.1210/jc.2010-2255
19. Šošic´-Jurjevic´ B, Filipovic´ B, Wirth EK, Živanovic´ J, Radulovic´ N, Jankovic´
S, et al. Soy isoflavones interfere with thyroid hormone homeostasis in
orchidectomized middle-aged rats. Toxicol Appl Pharmacol. (2014) 278:124–
34. doi: 10.1016/j.taap.2014.04.018
20. Filipovic´ B, Šošic´-Jurjevic´ B, AjdŽanovic´ V, Živanovic´ J, Manojlovic´-
Stojanoski M, Nestorovic´ N, et al. The phytoestrogen genistein prevents
trabecular bone loss and affects thyroid follicular cells in a male rat model
of osteoporosis. J Anat. (2018) 233:204–12. doi: 10.1111/joa.12828
21. Šošic´-Jurjevic´ B, Filipovic´ B, Renko K, AjdŽanovic´ V, Manojlovic´-Stojanoski
M, Miloševic´ V, et al. Orchidectomy of middle-aged rats decreases liver
deiodinase 1 and pituitary deiodinase 2 activity. J Endocrinol. (2012) 215:247–
56. doi: 10.1530/JOE-12-0336
22. Schomburg L, Riese C, Renko K, Schweizer U. Effect of age on sexually
dimorphic selenoprotein expression in mice. Biol Chem. (2007) 388:1035–
41. doi: 10.1515/BC.2007.128
23. Robbins J. Thyroid hormone transport proteins and the physiology of
hormone binding. In: Braverman LE, Utiger RD, editors. The Werner and
Ingbar’s the Thyroid—A Fundamental and Clinical Text. 8th ed. Philadelphia,
PA: Lippincott Williams &Wilkins (2000). p. 105–20.
24. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin
Endocrinol Metab. (2009) 23:769–80. doi: 10.1016/j.beem.2009.06.005
25. Capen CC. Mechanistic data and risk assessment of selected
toxic end points of the thyroid gland. Toxicol Pathol. (1997) 25:
39–48. doi: 10.1177/019262339702500109
26. Filipovic´ B, Šošic´-Jurjevic´ B, AjdŽanovic´ V, Brkic´ D, Manojlovic´-Stojanoski
M, Miloševic´ V, et al. Daidzein administration positively affects thyroid C
cells and bone structure in orchidectomized middle-aged rats. Osteoporos Int.
(2010) 21:1609–16. doi: 10.1007/s00198-009-1092-x
27. Živanovic´ J, Jaric´ I, AjdŽanovic´ V, Mojic´ M, Miler M, Šošic´-Jurjevic´
B, et al. Daidzein upregulates anti-aging protein Klotho and NaPi 2a
cotransporter in a rat model of the andropause. Ann Anat. (2019) 221:27–
37. doi: 10.1016/j.aanat.2018.08.001
28. Khalil DA, Lucas EA, Smith BJ, Soung DY, Devareddy L, Juma S, et al. Soy
isoflavones may protect against orchidectomy-induced bone loss in aged male
rats. Calcif Tissue Int. (2005) 76:56–62. doi: 10.1007/s00223-004-0018-z
Frontiers in Endocrinology | www.frontiersin.org 4 October 2019 | Volume 10 | Article 688
Šošic´-Jurjevic´ et al. Isoflavones, Pituitary-Thyroid Axis and Bone
29. Soung DY, Devareddy L, Khalil DA, Hooshmand S, Patade A, Lucas EA, et
al. Soy affects trabecular microarchitecture and favorably alters select bone-
specific gene expressions in a male rat model of osteoporosis. Calcif Tissue Int.
(2006) 78:385–91. doi: 10.1007/s00223-005-0069-9
30. Hertrampf T, Schleipen B, Offermanns C, Velders M, Laudenbach U, Diel
P. Comparison of the bone protective effects of an isoflavone-rich diet with
dietary and subcutaneous administrations of genistein in ovariectomized
rats. Toxicol Lett. (2009) 184:198–203. doi: 10.1016/j.toxlet.2008.
11.006
31. Picherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco
MJ, Lebecque P, et al. Daidzein is more efficient than genistein in
preventing ovariectomy-induced bone loss in rats. J Nutr. (2000) 130:1675–
81. doi: 10.1093/jn/130.7.1675
32. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH
is a negative regulator of skeletal remodeling Cell. (2003) 115:151–
62. doi: 10.1016/S0092-8674(03)00771-2
33. Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O’Brien S, et al.
Thyroid-stimulating hormone restores bone volume, microarchitecture, and
strength in aged ovariectomized rats. J Bone Miner Res. (2007) 22:849–
59. doi: 10.1359/jbmr.070302
34. Karga H, Papaioannou G, Polymeris A, Papamichael K, Karpouza A,
Samouilidou E, et al. The effects of recombinant human TSH on bone
turnover in patients after thyroidectomy. J Bone Miner Metab. (2010) 28:35–
41. doi: 10.1007/s00774-009-0098-y
35. Ringe JD. Glucocorticoid-induced osteoporosis. Clin Reumatol. (1989) 8:
109–15. doi: 10.1007/BF02207244
36. da Paz LH, Jorgetti V, Yoshinari NHAnimal models of osteoporosis. Rev Hosp
Clin Fac Med São Paulo. (1997) 52:86–9.
37. Kakucska I, Qi Y, Lechan RM. Changes in adrenal status affect
hypothalamic thyrotropin-releasing hormone gene expression in
parallel with corticotropin-releasing hormone. Endocrinology. (1995)
136:2795–802. doi: 10.1210/endo.136.7.7789304
38. Joseph-Bravo P, Jaimes-Hoy L, Charli J-L. Regulation of TRH neurons
and energy homeostasis-related signals under stress. J Endocrinol. (2015)
224:R139–59. doi: 10.1530/JOE-14-0593
39. Colaianni G, Cuscito C, Colucci S. FSH and TSH in the regulation of
bone mass: the pituitary/immune/bone axis. Clin Dev Immunol. (2013)
2013:382698. doi: 10.1155/2013/382698
40. Ohno S, Nakajima Y, Inoue K, Nakazawa H. Nakajin S. Genistein
administration decreases serum corticosterone and testosterone levels in rats.
Life Sci. (2003) 74:733–42. doi: 10.1016/j.lfs.2003.04.006
41. AjdŽanovic´ V, Šošic´-Jurjevic´ B, Filipovic´ B, Trifunovic´ S, Manojlovic´-
Stojanoski M, Sekulic´ M, et al. Genistein-induced histomorphometric and
hormone secreting changes in the adrenal cortex in middle-aged rats. Exp Biol
Med. (2009) 234:148–56. doi: 10.3181/0807-RM-231
42. Ariyani W, Iwasaki T, Miyazaki W, Yu L, Takeda S, Koibuchi N. A possible
novel mechanism of action of genistein and daidzein for activating thyroid
hormone receptor-mediated transcription. Toxicol Sci. (2018) 164:417–
27. doi: 10.1093/toxsci/kfy097
43. Williams AJ, Robson H, Kester MHA, van Leeuwen JPTM, Shalet SM, Visser
TJ, et al. Iodothyronine deiodinase enzyme activities in bone. Bone. (2008)
43:126–34. doi: 10.1016/j.bone.2008.03.019
44. Braun D, Schweizer U. The chemical chaperone phenylbutyrate rescues
MCT8 mutations associated with milder phenotypes in patients
with Allan–Herndon–Dudley syndrome. Endocrinology. (2017) 158:
678–91. doi: 10.1210/en.2016-1530
45. Renko K, Schäche S, Hoefig CS, Welsink T, Schwiebert C, Braun D, et
al. An improved nonradioactive screening method identifies genistein and
xanthohumol as potent inhibitors of iodothyronine deiodinases. Thyroid.
(2015) 25:962–8. doi: 10.1089/thy.2015.0058
46. Jiang Y, Gong P, Madak-Erdogan Z, Martin T, Jeyakumar M, Carlson K,
et al. Mechanisms enforcing the estrogen receptor β selectivity of botanical
estrogens. FASEB J. (2013) 27:4406–18. doi: 10.1096/fj.13-234617
47. Chin KY, Ima-Nirwana, S. Can soy prevent male osteoporosis? A
review of the current evidence. Curr Drug Targets. (2013) 14:1632–
41. doi: 10.2174/1389450114666131216222612
48. Hüser S, Guth S, Joost HG, Soukup ST, Köhrle J, Kreienbrock L, et al.
Effects of isoflavones on breast tissue and the thyroid hormone system in
humans: a comprehensive safety evaluation. Arch Toxicol. (2018) 92:2703–
48. doi: 10.1007/s00204-018-2279-8
49. Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale
S, et al. Sulfate metabolites provide an intracellular pool for resveratrol
generation and induce autophagy with senescence. Sci Transl Med. (2013)
5:205ra133. doi: 10.1126/scitranslmed.3005870
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Šošic´-Jurjevic´, Ajdžanovic´, Filipovic´, Severs and Miloševic´. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 5 October 2019 | Volume 10 | Article 688
